Ph.D., Pharmacology, University of Michigan, 1980
B.Sc., Biology (Cum Laude), University of Notre Dame, 1975
Professor and Tier I Canada Research Chair; Director, Institute of Parasitology, McGill University
Institute of Parasitology, McGill University
Professor and Canada Research Chair; Director, 2005-
The Upjohn Company (Pharmacia & Upjohn, Pharmacia, Pfizer), Parasitology Research
Research Scientist II - Associate Research Fellow, 1985-2005
Michigan State Univ., Dept. Microbiology and Public Health, Research Assistant Professor, 1984-1985
NIH Postdoctoral Fellow/Research Assistant, 1980-1984
NIH-SBIR Review Committee, 1989; Institute of Medicine-Malaria Research and Control, 1990-91; NIH - Minority Predoctoral Fellowship, 1991-1994; NIH-MBRS-Genetics review committee, 1995; NIH Training Grant site review committee (Biotechnology, Chemistry-Biology Interface, 1995); NIH-RFA for Tropical Medicine Research Centers, 1995; NIH-PTHE Study Section, 2006-2008; WHO/TDR - Macrofil Committee, 1991; Working Group on Compound Evaluation Network, 2006-; Steering Committee on Genomics and Discovery Research, 2006-; Helminth Initiative, 2006-; External Drug Advisory Committee, 2007-; American Society of Parasitologists, Student Awards Committee, 1991, 1992 (Chair); Priorities Committee, 1991-1993; Molecular Biology Symposium Organizing Committee, 1991-1994; Nominating Committee, 1995-1996, 1999-2001 (chair); Industrial Relations Committee, 1999-2003 (chair), 2006-; Bueding and von Brand Award Committee, 1999-2001 (chair), 2007-2010; American Association of Veterinary Parasitologists, Finance Committee, 1999-2000; Nominating Committee 2000-2002 (chair); Keystone Symposium on Molecular Helminthology, Co-organizer, 1993, 1996, 2001; USDA - Helminthic Diseases Laboratory External Review, 1993; Gent University Methusalem Awards Committee, 2008; IDRP/AIBS/WRAIR Antiparasitic discovery and development committee, 2010-; Expert Advisory Board, AWOL Gates Foundation Grant, 2007-; External grant reviews: CSIRO (Australia), Welcome Trust (UK), Stichting Levenswetenschappen (Netherlands), WHO (Geneva), NSF, IH (USA), US-Israeli Binational Foundation; Health Research Board, Ireland; Bill and Melinda Gates Foundation; Swiss National Science Foundation; NSERC - ITSC/GPP; BBRC; CIHR.
Associate Editor, The Journal of Parasitology, 1993-; Specialist Editor, International Journal for Parasitology, 2004-2010; Editorial Board, International Journal for Parasitology-Drug Discovery and Resistance, 2011-; Editorial Board, Parasitology, 2006-; Editorial Board, Parasites & Vectors, 2007-; Editorial Board, PLoS-Neglected Tropical Diseases, 2009-
I began my studies on the pharmacology of antiparasitic drugs as a postdoc at Michigan State University, working on chemotherapy of malaria in the lab and in the field. While at The Upjohn Company in Kalamazoo, I eventually was privileged to lead a team in antiparasitic drug discovery. Following the acquisition of the company by Pfizer, I chose to continue working in research and joined the Institute of Parasitology at McGill in 2005 as a Tier I Canada Research Chair. I became Director of the Institute in 2007. My research program focuses on genomic and proteomic analysis of the host-parasite interface, especially filarial and gastrointestinal nematode infections. We operate an African-centered research program for antiparasitic drug discovery and are involved in efforts to repurpose flubendazole for use in neglected tropical diseases. With Roger Prichard, we are investigating the possibility of drug resistance in Dirofilaria immitis.